- Report
- October 2024
- 187 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 200 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- October 2024
- 90 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- February 2025
- 282 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 147 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Drug Pipelines
- April 2024
- 200 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- May 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- September 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- October 2024
- 182 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- September 2024
- 179 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Clinical Trials
- August 2024
- 712 Pages
Global
From €3280EUR$3,450USD£2,755GBP
- Report
- January 2024
- 348 Pages
Global
From €5359EUR$5,835USD£4,350GBP
- Report
- May 2022
- 150 Pages
Global
From €2282EUR$2,400USD£1,917GBP
- Report
- October 2021
- 72 Pages
Global
From €761EUR$800USD£639GBP
- Report
- January 2024
- 250 Pages
Global
From €2329EUR$2,450USD£1,957GBP
- Report
- July 2022
- 112 Pages
Global
From €4278EUR$4,500USD£3,594GBP

The Cystic Fibrosis Drug market is a subset of the larger Respiratory Drug market. It is composed of treatments and therapies designed to address the symptoms of cystic fibrosis, a genetic disorder that affects the lungs and digestive system. These drugs are used to reduce the amount of mucus in the lungs, improve breathing, and reduce the risk of infection. They may also be used to treat other symptoms, such as malnutrition, dehydration, and vitamin deficiencies.
The Cystic Fibrosis Drug market is highly competitive, with many companies developing and marketing treatments. Some of the major players in the market include Vertex Pharmaceuticals, Gilead Sciences, Novartis, and GlaxoSmithKline. Other companies, such as AbbVie, Merck, and Pfizer, are also active in the market. Show Less Read more